Literature DB >> 16496935

Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis.

Timothy J Scase1, David Edwards, Jodi Miller, William Henley, Ken Smith, Anthony Blunden, Sue Murphy.   

Abstract

The Patnaik histologic grading system is commonly used to predict the behavior of cutaneous mast cell tumors (MCTs) in dogs, but it is less useful for grade 2 MCTs because they exhibit considerable variation in biological behavior. In this retrospective study, immunohistochemical staining for Ki-67, proliferating cell nuclear antigen (PCNA), and survivin and a standardized argyrophilic staining of nucleolar organizer regions (AgNOR) protocol were performed on 121 archived paraffin-embedded specimens of canine cutaneous MCTs, for which clinical follow-up data were available. Cox regression models indicated that the Ki-67 score (hazard ratio, 1.92; P < .001) and mean AgNOR score (hazard ratio, 2.57; P < .001) were significantly associated with Patnaik grade and survival time. A binary Ki-67 variable (cutoff point Ki-67 score = 1.8) was a significant predictor of survival for dogs with grade 2 MCTs. The estimated 1-, 2-, and 3-year survival probabilities for dogs with grade 2 MCTs and Ki-67 scores less than 1.8 were 0.92, 0.86, and 0.77, respectively (SEs, 0.08, 0.14, and 0.23, respectively; median not estimable). The corresponding survival probabilities for dogs with grade 2 MCTs and Ki-67 scores higher than 1.8 were 0.43, 0.21, and 0.21, respectively (SEs, 0.19, 0.18, and 0.18, respectively; median survival time, 395 days). No significant association was identified between survival and survivin score or PCNA score. This study shows that both mean AgNOR score and Ki-67 score are prognostic markers for canine MCTs. The Ki-67 score can be used to divide Patnaik grade 2 MCTs into 2 groups with markedly different expected survival times.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496935     DOI: 10.1892/0891-6640(2006)20[151:cmctco]2.0.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  16 in total

1.  Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas.

Authors:  Ahmad N Al-Dissi; Deborah M Haines; Baljit Singh; Beverly A Kidney
Journal:  Can Vet J       Date:  2010-10       Impact factor: 1.008

Review 2.  DCE-MRI: a review and applications in veterinary oncology.

Authors:  M Keara Boss; N Muradyan; D E Thrall
Journal:  Vet Comp Oncol       Date:  2011-12-08       Impact factor: 2.613

3.  The effect of prednisone on histologic and gross characteristics in canine mast cell tumors.

Authors:  Ken J Linde; Stephen L Stockdale; Michael B Mison; James A Perry
Journal:  Can Vet J       Date:  2021-01       Impact factor: 1.008

4.  Τhe Effect of Opioid Administration on Cytologic and Histopathologic Diagnosis of Canine Cutaneous Mast Cell Tumors Treated by Surgical Excision.

Authors:  Christina Marouda; Tilemahos Anagnostou; Ioannis Savvas; Lysimachos G Papazoglou; Dimitra Psalla
Journal:  Vet Sci       Date:  2022-04-22

5.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

6.  Prognostic utility of apoptosis index, Ki-67 and survivin expression in dogs with nasal carcinoma treated with orthovoltage radiation therapy.

Authors:  Dah-Renn Fu; Daiki Kato; Ai Watabe; Yoshifumi Endo; Tsuyoshi Kadosawa
Journal:  J Vet Med Sci       Date:  2014-08-25       Impact factor: 1.267

7.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

8.  Identification of two molecular subtypes in canine mast cell tumours through gene expression profiling.

Authors:  Lidia H Pulz; Camila N Barra; Pamela A Alexandre; Greice C Huete; Karine G Cadrobbi; Adriana T Nishiya; Silvio Henrique de Freitas; Heidge Fukumasu; Ricardo F Strefezzi
Journal:  PLoS One       Date:  2019-06-19       Impact factor: 3.240

9.  Identification of molecular genetic contributants to canine cutaneous mast cell tumour metastasis by global gene expression analysis.

Authors:  Kelly Bowlt Blacklock; Zeynep Birand; Deborah Biasoli; Elena Fineberg; Sue Murphy; Debs Flack; Joyce Bass; Stefano Di Palma; Laura Blackwood; Jenny McKay; Trevor Whitbread; Richard Fox; Tom Eve; Stuart Beaver; Mike Starkey
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240

10.  Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors.

Authors:  Rodrigo Dos Santos Horta; Antonio Giuliano; Gleidice Eunice Lavalle; Mariana de Pádua Costa; Roberto Baracat de Araújo; Fernando Constantino-Casas; Jane Margaret Dobson
Journal:  Oncol Lett       Date:  2017-11-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.